Biologic Switching Strategies for Anti–Tumor Necrosis Factor Alpha Refractory Noninfectious Uveitis:

Quick Take

This study evaluates biologic switching strategies for patients with noninfectious uveitis (NIU) who are refractory to anti-tumor necrosis factor alpha (TNFα) agents. The research aims to identify effective clinical pathways for maintaining inflammatory control when initial biologic therapies fail.

Why It Matters

Anti-TNFα agents are a cornerstone of systemic therapy for sight-threatening noninfectious uveitis, yet many patients eventually require a change in treatment due to inadequate response. There is currently a lack of standardized protocols for whether to cycle within the same class or switch to a different biologic mechanism. This investigation addresses a critical gap in managing recalcitrant ocular inflammation and preventing irreversible vision loss.

Study Snapshot

Practice Implications

Clinicians should closely monitor patients on anti-TNFα therapy for signs of refractory disease and be prepared to implement a strategic switch to alternative biologics. Identifying the most effective secondary treatment paths is essential for patients who fail to achieve inflammatory remission on first-line systemic agents.

Who's Affected